he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源位址
- 2022-04-26吡仑帕奈辅助用药可改善部分癫痫型癫痫患者的症状
- 2022-04-252013年国际抗癫痫联会抗癫痫药使用指南
- 2022-04-12藏红花的功效 这4种功效让女性对它爱不释手
- 2022-02-14青少年癫痫病病因有哪些啊
- 2022-01-10常见的癫痫病病因有哪些您究竟?
- 2019-04-15继发性癫痫反复发作的原因
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- 藏红花的功效 这4种功效让女性对它爱不释手
- 银屑病药物 Brodalumab 自杀倾向副作用AZ 遭受重创
- 抗癫痫药物预防新发癫痫:任重而道远
- 白癜风光疗有很多方法 因地制宜教你选择
- 比较好治疗增生性疣状白斑
- 贝安健康:常见的妇科炎症有哪些类型?
- 预测癫痫患者再入院风险
- 妇科解剖记忆公式有点长,非常详细!
- 煮螃蟹的方法 这样吃螃蟹味道也不错
- A&R: Semaphorin3B 在血清诱导的关节炎模型中发挥核心作用,减少类风湿性关节炎患者
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 什么是霉菌性阴炎?
- 凹进去怎么办?会是乳腺癌吗?!
- 不孕的原因是什么?
- 月经前后疼痛?这样的乳腺增生严重吗?
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 儿童白癜风的原因是什么 儿童白癜风怎么办?
- 心率多少正常 如何保持正常心率不变
- 癫痫治疗障碍仍难以克服
- 不注意这些问题,吃多少药都没用!
- 治疗类风湿性关节炎/膝骨关节炎的专家共识
- 不同年龄段白癜风患者的病因
- 脑梗死的症状是什么有这些前兆要谨慎
- Cell重磅:解决了近百年的问题!研究发现了闪过记忆的潜在机制
- 在转移机制研究方面取得了重大进展
- 白癜风症状 有些白斑可以预防白癜风
- 38癫痫患者年病史上的感谢信 道出了浓浓的医患情况
- 一种特异性的癫痫高烧类型【视频】
- 难治性癫痫年中状态剂该怎么用?
- 山西太原癫痫病医院:想要快点控制病情,这3大诊疗误区你一定要知道!
- 治疗癫痫病最难的方法是什么
- 癫痫病的如前所述治疗方法有哪些
- 于明治癫痫病能于明治的好么
- 癫痫病的副作用及治疗
- 【用药问答】控制脑瘤患者再抽搐, 可选用的药物不包括?
- 癫痫病的病因没错是什么
- 癫痫的呕吐是什么
- 怎么用科学的方法有治疗癫痫病
- 癫痫的症状及治疗方法 四种治疗方法周遭癫痫